Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Nov;96(11):3493-501.
doi: 10.1210/jc.2011-0501. Epub 2011 Aug 24.

Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment

Beata Banaszewska  1 , Leszek Pawelczyk, Robert Z Spaczynski, Antoni J Duleba
Affiliations
Randomized Controlled Trial

Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment

Beata Banaszewska et al. J Clin Endocrinol Metab. 2011 Nov.

Abstract

Context: A randomized trial on women with polycystic ovary syndrome (PCOS) compared simvastatin, metformin, and a combination of these drugs.

Objective: The aim of the study was to evaluate long-term effects of simvastatin and metformin on PCOS.

Design: Women with PCOS (n = 139) were randomized to simvastatin (S), metformin (M), or simvastatin plus metformin (SM) groups. Evaluations were performed at baseline and at 3 and 6 months.

Setting: The study was conducted at a university medical center.

Primary outcome: We measured the change of serum total testosterone.

Results: Ninety-seven subjects completed the study. Total testosterone decreased significantly and comparably in all groups: by 25.6, 25.6, and 20.1% in the S, M, and SM groups, respectively. Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. Dehydroepiandrosterone sulfate declined significantly only in the S group. Total cholesterol and low-density lipoprotein cholesterol significantly declined only in the S and SM groups. Ongoing reduction of ovarian volume, decreased hirsutism, acne and testosterone were observed between 0 and 3 months as well as between 3 and 6 months. Improvement of lipid profile, C-reactive protein, and soluble vascular cell adhesion molecule-1 occurred only during the first 3 months of treatment, with little change thereafter. Treatments were well tolerated, and no significant adverse effects were encountered.

Conclusions: Long-term treatment with simvastatin was superior to metformin. Improvement of ovarian hyperandrogenism continued throughout the duration of the study.

Trial registration: ClinicalTrials.gov NCT00396513.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Flow diagram of the trial.
Fig. 2.
Fig. 2.
Time-course of effects of simvastatin (S), metformin (M) and simvastatin plus metformin (S+M) on selected parameters of PCOS during the first 3 months of treatment (values at baseline in comparison to 3 months; hatched bars) and during the second 3 months (values at 3 months in comparison to values at 6 months; gray bars) of the trial. Each bar represents mean ± sem. *, P < 0.05. Different ranges and different scales are used for presentation of individual parameters.
See this image and copyright information in PMC

References

    1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. 2004. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749 - PubMed
    1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. 1999. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84:4006–4011 - PubMed
    1. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. 2000. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434–2438 - PubMed
    1. Nelson VL, Legro RS, Strauss JF, 3rd, McAllister JM. 1999. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 13:946–957 - PubMed
    1. Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF, 3rd, McAllister JM. 2000. Differential activity of the cytochrome P450 17α-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 85:2304–2311 - PubMed

Publication types

MeSH terms

Associated data